Case report<br>Omalizumab treatment in brittle asthma

Roman Skiepko; Ziemowit Zietkowski; Urszula Skiepko; Wojciech Budny; Mateusz Lukaszyk; Anna Bodzenta-Lukaszyk

doi:10.5114/pdia.2014.40658

eISSN: 2299-0046
ISSN: 1642-395X

Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii

Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

1/2014
vol. 31

Send email

Copy url:

abstract:

Case report
Omalizumab treatment in brittle asthma

Roman Skiepko

,

Ziemowit Zietkowski

,

Urszula Skiepko

,

Wojciech Budny

,

Mateusz Lukaszyk

,

Anna Bodzenta-Lukaszyk

Postep Derm Alergol 2014; XXXI, 1: 36–38

DOI: https://doi.org/10.5114/pdia.2014.40658

Online publish date: 2014/02/25

View full text Get citation

Asthma is a heterogeneous disease with variable characteristics such as lung function, symptoms and control, body weight, pattern of inflammation, and response to treatment. Brittle asthma is one of clinical phenotypes of asthma with unclear pathogenic mechanisms and appropriate treatment. Analysis of 2 described cases suggests that omalizumab could be useful in the treatment of brittle allergic asthma.

keywords:

Case reportOmalizumab treatment in brittle asthma

Roman Skiepko , Ziemowit Zietkowski , Urszula Skiepko , Wojciech Budny , Mateusz Lukaszyk , Anna Bodzenta-Lukaszyk

brittle asthma, omalizumab

Case report
Omalizumab treatment in brittle asthma

Roman Skiepko

,

Ziemowit Zietkowski

,

Urszula Skiepko

,

Wojciech Budny

,

Mateusz Lukaszyk

,

Anna Bodzenta-Lukaszyk